These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25638764)

  • 1. Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay.
    Boada Burutaran M; Guadagna R; Grille S; Stevenazzi M; Guillermo C; Diaz L
    Rev Bras Hematol Hemoter; 2015; 37(1):28-33. PubMed ID: 25638764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.
    Marini BL; Hough SM; Gregg KS; Abu-Seir H; Nagel JL
    Support Care Cancer; 2015 Aug; 23(8):2287-95. PubMed ID: 25576429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
    Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
    Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
    Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
    Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.
    Kamonrattana R; Sathitsamitphong L; Choeyprasert W; Charoenkwan P; Natesirinilkul R; Fanhchaksai K
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2733-2737. PubMed ID: 31554370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
    Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
    Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
    Fleischhack G; Schmidt-Niemann M; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    Support Care Cancer; 2001 Jul; 9(5):372-9. PubMed ID: 11497392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia.
    Baskaran ND; Gan GG; Adeeba K; Sam IC
    Int J Infect Dis; 2007 Nov; 11(6):513-7. PubMed ID: 17459753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Rizal AM; Nordiah AJ; Jamal R
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
    Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
    Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-risk febrile neutropenia in a medical oncology unit.
    Leong DC; Kinlay S; Ackland S; Bonaventura A; Stewart JF
    Aust N Z J Med; 1997 Aug; 27(4):403-7. PubMed ID: 9448881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country.
    James V; Prakash A; Mehta K; Durugappa T
    Infect Agent Cancer; 2021 Jun; 16(1):44. PubMed ID: 34147094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fever and neutropenia in children with malignant disease.
    Roguin A; Kasis I; Ben-Arush MW; Sharon R; Berant M
    Pediatr Hematol Oncol; 1996; 13(6):503-10. PubMed ID: 8940733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.